PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA Russian patent published in 2023 - IPC A61K51/04 C07D257/02 A61P35/00 A61P13/08 

FIELD: organic and medicinal chemistry, oncology.

SUBSTANCE: invention relates to the field of radiopharmaceuticals intended for use as theranostic agents for the diagnosis and therapy of prostate cancer. The technical result of the claimed invention is to expand the arsenal of theranostic agents for selective targeting and penetration into pathogenic tumor tissues expressing PSMA, while simultaneously providing excellent cellular uptake and internalization characteristics at relatively low conjugate concentrations. The technical result is achieved by a PSMA-targeted compound to obtain a radionuclide-labeled complex intended for theranostics of tumors expressing PSMA, with the general formula Glu-Urea-Lys-2-naphthyl-L-alanine-L-tyrosine-8Aoc-Lys-DOTA-acetamide. The complex for theranostics of tumors expressing PSMA includes a PSMA-targeting compound with a radionuclide label, which is the radionuclide ¹⁷⁷Lu.

EFFECT: obtaining PSMA-target compound and its complex with radionuclides for theranostics of tumor expressing PSMA.

2 cl, 8 dwg, 1 ex